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Abstract
Background: The growth of chain pharmacies in India, and other low- and middle-income countries (LMICs), 
is challenging the status quo of pharmacy retail markets which have historically been dominated by independent 
pharmacies. This raises the question of whether such organisations will have a positive impact on affordability and 
access to medicines. 
Methods: This paper draws on a standardised patient (SP) survey to measure the prices of medicines and expenditure 
on consultations for two tracer conditions (suspected tuberculosis [TB] in an adult and diarrhoea in an absent child) 
at a random sample of 230 chain and independent pharmacies in Bengaluru. Asset data were collected from 808 exit 
interviews with pharmacy customers to determine socioeconomic profiles of clients. 
Results: Chain pharmacies were found to provide lower priced medicines for patients seeking care for diarrhoea and TB, 
with expenditure also lower for diarrhoea patients, compared to independent pharmacies. This was seemingly driven 
by lower prices rather than number of medicines dispensed or prescribing habits. Despite the availability of cheaper 
medicines, chains served wealthier clients, compared to independent pharmacies. 
Conclusion: The findings indicate the potential for chains to contribute to improving medicine affordability as they 
expand. However, any attempt to leverage this organisational model for public health good would need to take account of 
the current client-mix of these pharmacies and be accompanied by appropriate regulatory constraints in order to realise 
the potential benefits for poorer groups. 
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Implications for policy makers
• Chain pharmacies in Bengaluru, India, were found to provide lower priced medicines compared to independent pharmacies for patients seeking 
care for diarrhoea and tuberculosis (TB).
• Chain pharmacies have the potential to contribute to improving medicine affordability as they expand. 
• Chains are currently patronised by relatively wealthy clients, indicating that such cost-reductions are currently disproportionately benefiting 
higher socioeconomic status (SES) groups. 
• Any attempt to leverage the chain pharmacy model for public health good should be accompanied by appropriate regulatory constraints to 
ensure benefits are extended to poorer groups. 
Implications for the public
Access to affordable medicines is a key concern in many low- and middle-income countries (LMICs). This study, conducted in urban India, found 
that chain retail pharmacy medicine prices were lower relative to medicines sold in independent pharmacy prices for two conditions. However, 
the customers using chain pharmacies and benefitting from these price reductions are currently relatively wealthier than those using independent 
pharmacies. Despite the high-end look and feel of chain pharmacies, potential customers (especially poorer groups) should be aware of these price 
differences.  
Key Messages 
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Background 
Retail pharmacies represent an important component of the 
health system in low- and middle-income countries (LMICs). 
Owing to their geographical accessibility, long opening hours, 
and availability of medicines they are often patients’ first port 
of call when illness arises.1 Pharmacy retail markets in LMICs 
have traditionally been dominated by local, independently 
owned pharmacies.2,3 These pharmacies are widely used but 
their practice has been judged to be poor. Insufficient history 
taking, a lack of adherence to treatment guidelines, and 
inappropriate dispensing of medicines are commonplace.1,4,5 
Moreover, up to 90% of the population in LMICs purchase 
medicines through out-of-pocket payments, with medicines 
accounting for the largest family expenditure item after food.6 
As a result, medicines are unaffordable for many. 
As the retail pharmacy market has matured, the entry of 
chain pharmacies has been noted in Africa, Asia and South 
America, with a particular presence in countries such as 
India, The Philippines, Mexico, Brazil, Chile, South Africa, 
Nigeria, Kenya, and Uganda.2,3,7 This has led to emerging 
interest amongst the global health community in the potential 
for chains to improve pharmacy services. In particular, there 
are reasons to believe that chains have the potential to reduce 
prices in comparison to independent pharmacies, making 
them a welcome addition from an access to medicines 
perspective. Chains may be able to take advantage of scale 
economies to invest in cost-reducing and quality-enhancing 
technologies.8 They may buy directly from manufacturers, 
thus by-passing the serial mark-ups associated with a 
complex supply chain. Additional savings could be made if 
chains became large enough to experience buying power in 
the market. In high-income countries, experience has shown 
that pharmacy chains pass these cost savings on to customers 
and many compete on the basis of price.9-11 
Moreover, cost to patients depends on both price and 
product-mix dispensed. If chain staff receive fixed salaries 
and therefore face lower-powered incentives than those of 
independent pharmacy owners, they may be less likely to 
encourage poly-pharmacy and purchase of more expensive 
products and brands.12 In contrast, the profit-related 
incentives of independent pharmacy owners could lead to 
unnecessary, and sometimes inappropriate, dispensing.4 
However, chain employees may also face high-powered 
incentives if they are heavily rewarded for achieving sales 
targets.13 It is also possible that, rather than passing on any 
cost savings to patients in the form of cheaper medicines, 
chain pharmacies may use their greater brand power to raise 
prices. In addition, in many settings, chains may operate in 
relatively affluent neighbourhoods,8 and provide relatively 
high-end services, with better infrastructure, more qualified 
staff and additional facilities, which could feed through into 
higher drug prices. 
To date, research on price and expenditure in this evolving 
segment of LMIC pharmacy markets has been very limited. 
Only one study by Bennet and Yin was identified, which 
investigated the effect of chain entry on quality and prices 
of medicines in local markets in Hyderabad, India. They 
worked with a leading Indian pharmacy chain, MedPlus, 
using standardised patients (SPs) to collect data on medicine 
price and chemical quality of two antibiotics in independent 
pharmacies in markets with and without a MedPlus entrant, 
before and after chain entry. The resulting effect of chain 
entry on the market (compared with control markets) was a 
relative 5% improvement in drug quality and a 2% decrease in 
prices at existing independent retailers.7
This paper aims to build on this limited evidence base 
by exploring prices of medicines and expenditure for two 
conditions – diarrhoea in a child and tuberculosis (TB) in 
an adult – utilising SPs at a random sample of chain and 
independent pharmacies in Bengaluru, India. To further 
explore the consequences of chain pharmacies for medicine 
access, we also compare the socioeconomic status (SES) of 
patients visiting chain and independent stores, based on exit 
interviews with real clients. 
Methods
Study Setting
Chains account for around 4% of India’s 800 000 pharmacies 
but their rate of growth is rapid.3 The chains are concentrated 
in India’s big cities, with a larger presence in the South. This 
guided the choice of Bengaluru, the capital of the Southern 
Indian state of Karnataka and India’s third most populous 
city, as the site for this work. Bengaluru has a population of 
around 10 million, and despite its relatively favourable human 
development indicator score (0.753) and literacy rate (88.7%), 
income disparities are stark. On the one hand, the city is known 
as ‘The Silicon Valley of India’ with a booming, international 
IT industry and a growing middle class; yet on the other, it is 
home to 597 of Karnataka’s 2804 identified slum communities, 
where many inhabitants live below the poverty line.14 The 
average daily wage for salaried, urban workers in Karnataka 
was reported to be 519 Rs ($7.05) and 392 Rs ($5.33) in 2011-
2012 for men and women, respectively.15 The median income 
of inhabitants living in one of Bengaluru’s slums is reportedly 
$1.5 (US) per day.16 Out of pocket expenditure accounts for 
over 70% of healthcare spending in India, indicating that most 
patients pay for their own medicines.17 Health-related costs 
have been shown to push Bengaluru residents into poverty.16 
At the time of data collection (November 2014-June 2015) 
there were 13 chains operating in the city, accounting for 529 
(9%) of Bengaluru’s 5664 registered retail pharmacies.18 Chain 
size varied from two to over two hundred outlets and five 
chains also owned pharmacies outside of Karnataka. There 
are notable physical differences between the two pharmacy 
types: independent stores tended to have an open, on-the-
street shop frontage, whereas most chains were enclosed, with 
air conditioning, and appeared neatly organised. Both chains 
and independent pharmacies stock a mix of innovator brands 
(brands under patent); ‘branded’ generics (products produced 
by Indian manufacturers, who advertise their products 
heavily in order to establish a reputation and improve market 
power8); and less commonly, non-branded generic products 
labelled only by the active ingredient. In India a distinction is 
made between ‘national’ and ‘local’ medicine manufacturers. 
National manufacturers tend to comply with Indian and 
international quality standards, whereas local manufacturers 
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(who often produce non-branded generics) are difficult to 
regulate due to their vast numbers. Retail pharmacies stock a 
high number of nationally and locally produced products for 
common medicines in order to accommodate a wide range of 
doctor and customer preferences. Each manufacturer dictates 
a maximum retail price (MRP) for their product but the MRP 
for a particular compound can vary across brands. There 
is therefore some scope for price variation through brand 
substitution. The National Pharmaceutical Pricing Authority, 
an independent body, also stipulates a ceiling price for some 
essential medicines.19 
Study Design and Data
Standardised Patient Survey
Price data were collected by means of an SP survey. SPs are 
healthy, undercover fieldworkers trained to present with 
specific symptoms and history, and to record the care they 
receive.20 This method has been increasingly used to measure 
quality of care in pharmacy settings over the past decade.21 
It is widely considered the gold standard in terms of quality 
of care measurement; the standardised presentation allows 
for direct comparison between providers, and it is free from 
the Hawthorne effect.20 SP data were utilised to compare 
outcomes in chain versus independent pharmacies, including 
deviation of medicine prices from the MRP, expenditure 
on the diarrhoea and TB case, and number of medicines 
dispensed. 
A stratified sample of chain (103) and independent (230) 
pharmacies were chosen, at random, from the Karnataka 
State Drug Control Department’s list of licensed pharmacies 
in Bengaluru. A small census verified that this list provided 
a comprehensive sampling frame. Sample size calculations 
were based on differences in quality measurements between 
pharmacy types (see Miller and Goodman18 for more details). 
The sample included eight of Bengaluru’s 13 chains – the 
largest seven and one of the six chains with 2-5 outlets. Six 
research assistants were trained to visit pharmacies and 
present standardised cases of diarrhoea in an (absent) child 
and suspected TB in the presenting adult. A substantial 
component of the training involved role play to practice 
both the presentation of the cases and personal back stories. 
SPs completed a number of pilots under the supervision of 
a senior research assistant, until we were confident that the 
presentations and associated dialogue would be perceived 
as authentic. The scenarios were presented in Kannada (the 
local language) and it was discussed how researchers should 
dress to ensure they appeared similar to a typical customer. 
At each pharmacy the SPs purchased any medicines that were 
recommended during the interaction and recorded the price 
of each individual medicine sold in a debrief questionnaire, 
completed immediately after each visit.
Exit Interviews With Patients 
We conducted exit interviews with real customers at the same 
random sample of pharmacies used for the SP survey. During 
a second visit to the pharmacies, researchers approached each 
customer that left the pharmacy and, if they agreed to take 
part, administered the exit interview to up to 3 customers per 
outlet, covering personal characteristics, reasons for visiting 
the pharmacy, and ownership of a number of assets. A total 
of 808 exit interviews were completed[1], deriving from 103 
chain outlets and 166 independent outlets. 
We utilised an asset-based approach to measure and 
compare the wealth of pharmacy customers visiting chain 
and independent pharmacies.22 We collected data on a subset 
of assets contained within the national District Level Health 
Survey (DLHS) (2012-2013), selecting assets relevant to the 
Bengaluru city context[2]. For example, we did not ask about 
ownership of a tractor or cart driven by an animal as these 
are more applicable for rural areas. Others have shown this to 
be a valid approach in both India and elsewhere.23,24 We were 
then able to compare the wealth of our patient sample with 
that of the general population residing in the same district 
(Bengaluru urban district, Karnataka). 
Analysis
Standardised Patient Survey 
Analysis of price data was conducted only on pharmacies 
who sold medicines (some SPs were referred to a physician 
without being sold any medicines). Data from the childhood 
diarrhoea and TB case were analysed separately using Stata 15. 
To examine prices of medicines sold at chain and independent 
pharmacies in a standardised way, across different medicine 
types, we calculated the difference between the actual price 
paid for medicines by SPs and the MRP, presenting both mean 
(accompanied by standard deviations and t test) and median 
price differences, interquartile range, and P value from the 
Wilcoxon rank sum test of the hypothesis of equal medians in 
chains and independents. We also calculated expenditure per 
encounter and used regression analysis to explore the effect of 
outlet type on expenditure. 
To explore the effect of product mix on expenditure we 
conducted a regression analysis to assess the relationship 
between expenditure for the diarrhoea case and sale of 
prescription only medicines (POMs) in general, and more 
specifically, antibiotics, the most commonly dispensed POM 
type. Prior work had revealed that chains dispensed fewer 
POMs and fewer antibiotics for diarrhoea.18 
Exit Interviews
We derived our SES indices using principal components 
analysis (PCA) in Stata 15. Using the DLHS data only, we 
generated a wealth asset score using PCA applied to the 
subset of assets measured in both the DLHS and the patient 
exit survey. We then generated a wealth asset score in the 
patient exit data by applying the PCA weights from the 
aforementioned data.22 We then split the DLHS sample into 
wealth quintiles, as described by Filmer and Pritchett25 and 
applied the same asset score quintile cut-offs to the patient exit 
sample. We compared the relative economic status of clients 
patronising chains and independents, as well as comparing 
our sample to the general population of Bengaluru. 
In order to investigate whether these apparent wealth 
disparities between chain and independent customers were 
driven by the location of chains (potentially in wealthier 
areas), we conducted additional analysis on a subsample of 
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pharmacies to compare the wealth of clients of chain and 
independent pharmacies that are in close proximity (on 
the basis that the SES of the catchment population is likely 
to be similar). For this purpose, we utilised ArcGIS to plot 
the Global Positioning System (GPS) locations of sample 
pharmacies. We then excluded chain pharmacies without an 
independent within 1km, and vice versa, and repeated the 
same analyses. 
Results 
Of the 333 shops visited by SPs, 67/103 chains (65%) and 
151/230 independents (66%) sold medicine(s) to the patient 
with suspected TB. For the diarrhoea patient, these figures 
were 63/103 (61%) and (153/230) 67% for chains and 
independents, respectively.
Price 
Individual medicines for diarrhoea were sold at a price below 
the MRP at both chains and independents, but the discount 
was larger for chains (0.9 rupees versus 0.15 rupees, P = .005) 
(Table 1). Whilst 0.9 Rupees (US$ 0.014) appears to be a small 
discount, the mean price difference in chains expressed as a 
percentage of the MRP was 6%. The median price difference 
for both chains and independents was zero. For medicines 
sold for TB symptoms, there was weak evidence that chains 
had lower prices relative to the MRP (discount of 0.03 
rupees in chains compared with 1.44 rupees over the MRP in 
independents, P = .097). The median difference between price 
paid for TB medicines and MRP was 0.2 rupees in chains and 
0 in independents (P = .059). 
Expenditure
In terms of expenditure by the SP, diarrhoea encounters 
at chains had a mean cost of 27.5 rupees (median 19) 
(Table 1). These encounters were significantly more expensive 
at independent pharmacies with a mean cost of 35.6 rupees 
and median of 38 (P = .011 and P = .002, respectively). 
There was no evidence of a difference between chains and 
independents in terms of expenditure for the TB encounter. 
Expenditure per condition is a function of the prices of the 
medicines sold, the mean number of medicines sold, and the 
product mix. The number of medicines sold did not differ at 
chain and independent pharmacies (1.2 at both outlet types 
for diarrhoea). 
The effect of product mix on expenditure is explored in 
Table 2. Model 1 shows that chains were 23% cheaper[3] than 
independent pharmacies, after controlling for SP fixed effects 
(P = .014). Model 2 explores the effect of number of medicines 
sold; the chain dummy is unchanged in this model indicating 
price differences are not explained by differences in dispensed 
medicines. Model 3 shows that whether a POM was sold had 
little effect on the coefficient on the chain dummy, while 
model 4 shows that controlling for whether an antibiotic was 
sold reduced the coefficient on the chain dummy, but did not 
eliminate it, indicating antibiotic purchase may explain part 
but not all of the observed price difference.
Table 1. Price Difference of Medicines Sold to SPs From the MRP, Number of Medicines Received, and Expenditure Per Encounter (Rupees) for Chain and Independent 
Pharmacies (Rupees)
Diarrhoea Case TB Case
Chains Independents P Value Chains Independents P Value
Mean price difference (SD) -0.90 (2.34) -0.15 (1.71) .005 0.03 (6.04) 1.44 (6.67) .097
Median price difference (IQR) 0 (-1.87 to 0.46) 0 (0 to 0.33) .316 0 (-0.87 to 0.60) 0.2 (0 to 1.12) .059
Mean number of medicines received 1.21 1.22 .886 1.37 1.51 .171
Mean expenditure (SD) 27.5 (18.3) 35.6 (22.1) .011 46.4 (26.8) 42.7 (38.5) .473
Median expenditure (IQR) 19 (13 to 37) 38 (18 to 47) .002 49.5 (20 to 64) 29 (11 to 64) .226
Abbreviations: SPs, standardised patients; MRP, maximum retail price; TB, tuberculosis SD, standard deviation; IQR, interquartile range.
Price difference = price paid - MRP.
Table 2. Effect of Pharmacy Type on Price: Diarrhoea Encounter
Dependent Variable
ln (Price)
Model 1 Model 2 Model 3 Model 4
Chain pharmacy -0.258a (0.104) -0.259b (0.997) -0.249a (0.094) -0.229a (0.968)
SP fixed effects Yes Yes Yes Yes
Number of medicines - 0.448b (0.105) 0.438b (0.106) 0.427b (0.102)
Prescription only - - 0.083 (0.103) -
Antibiotics - - - 0.356b (0.091)
Observations 216 216 216 216
R2 0.04 0.12 0.12 0.15
Abbreviation: SP, standardised patient.
Standard errors in parentheses.
a P <  .050, b P <  .010.
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Socioeconomic Profile of Clients
Figure shows the distribution across wealth quintiles of 
customers visiting chain and independent shops in our 
sample, compared to that of the general population. The 
figure shows a clear pattern of higher wealth of independent 
customers compared to the general population. Chain 
customers were found to be relatively wealthy compared to 
both the general population and independent customers. The 
clearest difference can be seen in the highest wealth category 
(quintile 5) which comprises 20% of the general population, 
compared to nearly half (45%) of independent customers and 
the majority (67%) of chain customers. Chi2 tests showed that 
differences in Q5 between the three groups were significant 
(P < .001 for all tests). 
We repeated the analyses on a geographically matched 
dataset (not shown), which included 264 exit interviews 
from 90 independents and 237 exit interviews from 79 
chains. The results were very similar to our original results 
in terms of customer wealth. The percentage of customers in 
the top quintile increased by 1 percentage point to 46% for 
independents and decreased to 66% (1% point) for chains, 
with the difference between the two, remaining significant 
(P < .001). 
Discussion 
This work used SPs to assess the actual prices of medicines 
sold in a large, representative sample of pharmacies in a 
major urban centre. We showed that prices of medicines 
sold at chain pharmacies were cheaper compared to those 
at independent pharmacies. Chains were undercutting 
the MRP more substantially than independents for the 
diarrhoea case. For the TB case, chain medicines followed 
the MRP and independents were charging more than the 
MRP (this difference was significant at the 10% level). In 
terms of expenditure by SP case, the diarrhoea encounter was 
significantly cheaper at chains and no difference was found 
for the TB case. Even after controlling for SP fixed effects and 
number of medicines sold, regression analyses showed that the 
diarrhoea encounter was 23% cheaper in chains, compared to 
independents (P < .010). This difference appears to be driven 
mainly by chains undercutting the MRP significantly more 
than independent pharmacies, although the sale of fewer 
antibiotics may also be a contributing factor. It is important 
to note that in absolute terms, chains were found to undercut 
the MRP by a very small amount (0.9 Rupees on average). 
When expressed as a percentage of the MRP, the mean price 
difference was -6%. 
There are two reasons why our price data may actually 
underestimate the price-cutting impact of chains. Firstly, 
most chains offer up to 10% discount on medicines to repeat 
customers which is not entirely captured by our SP patients who 
are unknown, first-time visitors to the pharmacy. Secondly, 
there are possible price spill over effects to independents, 
who may have decreased their prices in response to price 
competition from chains. Bennet and Yin8 showed that after 
the entry of a chain into a local retail pharmacy market, the 
price at independent shops fell by a non-significant 2%-
4%. However, for non-national brands alone they found a 
significant 12%-15% price reduction. Similar spillover effects 
follwing the entry of low-cost chains have also been observed 
in other industries.26,27 The 6% reduction in MRP observed 
at chain pharmacies combined with 10% discounts for 
regular customers would result in meaningful medicine price 
reductions for many. Discussions with local chain executives 
revealed that these price reductions are possible due to 
exploitation of scale economies and the operational efficiency 
of the chain model. Bulk purchasing reportedly enables larger 
chains to enjoy purchasing discounts of around 3 to 7%. 
Further, their procurement processes usually bypass at least 
one layer of the supply chain. The use of technology in high-
income country chains has been associated with increasing 
operational speed.28 
Customers shopping at chain pharmacies were better-off 
relative to those patronising independents. These results 
held after restricting the analysis to chain and independent 
pharmacies situated within 1km of each other, indicating that 
this finding was not purely driven by chain location. This may 
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Figure. Wealth of Customers Patronising Chain and Independent Pharmacies Relative to the General Population of Bengaluru. Abbreviation: DLHS, District Level 
Health Survey.
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offering credit to those who cannot afford to buy medicines 
(which was reported in accompanying qualitative work). 
Additionally, the chains in Bangalore generally had a more 
high-end feel in terms of appearance, meaning that they may 
have been off-putting or intimidating to lower income groups. 
It is possible that the socio-economic mix of chain clients will 
change as the market evolves. Other industries have seen 
diffusion of retail chains in LMICs from big to smaller cities, 
and from upper to middle to poorer classes,29 meaning that 
we may see more lower-income chain patients over time. 
The higher SES of chain clients suggests that the relatively 
wealthy may be more sensitive to quality. This raises the 
question of whether wealthier clients are also getting better 
quality of care by patronising chains? Evidence on this is 
limited and inconclusive. Accompanying results from this 
project found no difference in quality of care in terms of 
case management, though chain pharmacies did sell fewer 
prescription only and harmful medicines to the diarrhoea SP 
but not to the TB one.18 Bennet and Yin found that medicines 
sold in chains were of similar pharmacopeial quality to those 
in independents.7 It is also feasible that customers perceive 
that a chain with better infrastructure will offer better quality 
medicines. 
It is also noteworthy that the profile of independent 
customers in our sample was considerably wealthier than 
that of the general population, indicating that the poorest 
members of the population were under-represented in both 
pharmacy types. This may reflect the high use of “informal 
providers” by poorer groups in India, who treat common 
illnesses with allopathic medicines, but have no government-
recognised medical degree, or legal regulatory status.30-32 
The above results are drawn from looking at prices for only 
two conditions and would not be generalisable to outside 
urban areas, where chains are still very rare. However, they 
are likely relevant in the context of other Indian cities because, 
although different chains may predominate in these settings, 
there is no indication of major variation in business models.13 
Evidence on chain pharmacies from other LMICs, in terms 
of price, SES of customers, and quality is lacking. In China, 
chain pharmacies reportedly have more stringent recruitment 
processes and training systems in place than independents.33 
A nationwide survey reported that pharmacists working 
in chains had a better understanding of the concept of 
‘pharmaceutical care.’ Further a higher percentage of chain 
pharmacists agreed that it was their duty to carry out such 
care and engage in practices such as provision of counselling 
to accompany the sale of medicines, monitoring for adverse 
drug reactions, and promoting drug safety. In Indonesia 
and Malaysia, chains are thought to provide better services 
than their independent counterparts, although there is little 
empirical evidence to support these claims.34,35 We did not 
identify any other studies from LMICs on relative price of 
medicines or SES of customers at chains and independents. 
Turning to the future for chain pharmacies, it is likely that, 
due to their ability to provide medicines at a lower price 
compared to independents, they will continue to expand 
their presence across India. Given that higher SES clients 
are currently the main benefactors of these lower prices, a 
set of requirements may be necessary to ensure that chain 
expansion includes presence in lower-income areas. If policy 
makers were interested in encouraging the development of 
chains, there are a number of regulatory or fiscal levers that 
could be set in motion to allow for this. These include tax 
breaks, relaxing licensing procedures, or liberalisation of 
foreign direct investment (FDI) for multi-brand retail trading 
(into which category the selling of pharmaceuticals falls). In 
2012 the Government permitted FDI up to 51% of the equity 
of Indian entities engaged in such retailing.36 However, these 
investors are subjected to a host of conditions. In 2018 the 
Union Cabinet approved 100% FDI in single-brand retail but 
such relaxation has not yet been extended to multi-brand 
retail.37 However, based on current evidence the justification 
to utilise such levers to encourage the growth of chains on 
public health grounds in India remains weak. 
Conclusion
In urban Bengaluru chain pharmacies were found to provide 
lower priced medicines for patients seeking care for diarrhoea 
and TB, with expenditure also lower for diarrhoea patients, 
compared to independent pharmacies. This indicates the 
potential for chains to contribute to improving medicine 
affordability as they expand, likely reflecting scale economies, 
more direct supply chains and greater purchasing power. 
However, despite these lower prices, chains were patronised 
by relatively wealthy clients, indicating that such cost-
reductions are currently disproportionately benefiting higher 
SES groups. Any future attempt to leverage this organisational 
model for public health good would need to take account of the 
current client-mix of these pharmacies, and be accompanied 
by appropriate regulatory constraints in order to realise the 
potential benefits for poorer groups.
Acknowledgements
We would like to thank the Society for Community Health 
Awareness Research and Action, Bengaluru, in particular 
Dr. Thelma Narayan, for providing office space, support and 
guidance during the data collection process. We are grateful 
to Dr. Timothy Powell-Jackson for providing advice and 
commenting on an earlier draft of this manuscript. 
Ethical issues 
Ethical approval was obtained from The London School of Hygiene and Tropical 
Medicine Ethics Committee, London, UK, and the Society of Community Health 
Awareness Research and Action Institutional Scientific and Ethics Committee 
in Bengaluru, India. We obtained written consent for the exit interviews and 
received a consent waiver for the SP study. This approach has been used in a 
number of SP studies where the services being researched are accessible to 
the general public and data collection poses minimal risk to providers.20
Competing interests 
Authors declare that they have no competing interests. 
Authors’ contributions 
RM and CG designed the study; RM oversaw data collection and analysed the 
data, CG contributed to data interpretation; RM drafted manuscript and CG 
provided critical review and comments.
Funding
This work was supported by an Economic and Social Research Council (ESRC) 
Miller and Goodman 
International Journal of Health Policy and Management, 2020, x(x), 1–7 7
PhD studentship and an ESRC post-doctoral fellowship [grant number ES/
T006854/1].
Endnotes
[1] Clients who refused to participate in exit interviews were not recorded, so it 
was not possible to calculate a response rate. 
[2] Refrigerator, telephone (landline), mobile phone, sewing machine, tap/
running water, radio, scooter/motorcycle, washing machine, car/jeep/van, 
watch/clock, computer without internet, computer with internet, cooler/AC, 
number of bedrooms.
[3] (e-0.2578 – 1)*100 = -22.7. 
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